Company Filing History:
1 out of 163 
1 out of 1,454 
Years Active: 2024
Title: Benedikte Serruys: Innovator in Cancer Treatment
Introduction
Benedikte Serruys is a notable inventor based in Sint-Michiels, Belgium. She has made significant contributions to the field of cancer treatment through her innovative research and development of novel therapeutic agents.
Latest Patents
Serruys holds a patent for "Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor." This technology aims to provide a new type of drug for treating individuals suffering from cancer. The invention includes polypeptides that consist of at least four immunoglobulin single variable domains (ISVDs), where one ISVD binds to T cell receptors (TCR) and at least two ISVDs bind to glypican-3 (GPC3). Additionally, the technology encompasses nucleic acids, vectors, and compositions that enhance its therapeutic potential.
Career Highlights
Throughout her career, Benedikte Serruys has worked with prominent companies in the biotechnology and pharmaceutical sectors. Notably, she has been associated with Ablynx N.V. and Sanofi, where she has contributed her expertise in drug development and innovation.
Collaborations
Serruys has collaborated with esteemed colleagues, including Daniel Janssen and Carlo Boutton, to advance her research and bring innovative solutions to the market.
Conclusion
Benedikte Serruys is a pioneering inventor whose work in developing targeted cancer therapies showcases her commitment to improving patient outcomes. Her contributions to the field are invaluable and reflect her dedication to scientific advancement.